Researchers at New Jersey’s Rutgers University have developed a new approach to stopping viral infections based on live-attenuated, replication-defective DNA virus vaccine.

The method was tested to produce a weakened or “attenuated” version of a mouse cytomegalovirus, a common virus, that has been altered so it can’t reproduce or replicate inside the cell. A replication-defective DNA virus is incapable of replicating its genome, and as a result, is unable to produce an infectious progeny virus in infected cells. 

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

When the weakened viral particles are injected into animals, they stimulate a specific host’s immune system to recognize the invading live virus particles as foreign, causing the virus to be eliminated whenever it is detected.

The new approach, published in Cell Reports Methods, effectively shut down viral infections in lab animals. “We have found that this method is safe; the attenuated virus infects certain cells without proliferating beyond that, and alerts the host to produce specific neutralizing antibodies against it,” says Dabbu Jaijyan, coauthor and researcher in the Department of Microbiology at Rutgers New Jersey Medical School. “We see this as a novel method that we hope will accelerate vaccine development for many untreated viral infections in humans and animals.”

The method specifically targets DNA viruses that reproduce by making copies of their DNA molecules. These include cytomegalovirus, chicken pox and herpes simplex. The researchers showed that the method is effective in mice against several DNA viruses, including human cytomegalovirus, mouse cytomegalovirus and herpes simplex virus 1 and 2.

“One of the major advantages of our technology is the safety offered by the robust inhibition of virus replication and that no progeny viruses are produced,” Jaijyan says. “Our technology can be easily applied to any DNA virus to generate live-attenuated replication defective viruses for vaccine development.”

The DNA virus vaccine method works specifically with DNA viruses because the researchers treat the cytomegalovirus particles destined for use in the vaccine with centanamycin. The compound is known as a DNA-binder because it latches onto organisms’ DNA, including that of DNA viruses, blocking reproduction.

The team is looking to eventually test the method in humans, with the goal to treat cytomegalovirus and other DNA-virus infections. Cytomegalovirus is a common virus and doesn’t usually cause illness in healthy individuals. However, infection with cytomegalovirus can have severe consequences in immunocompromised and organ transplant patients. Congenital infection also is the leading cause of birth defects in newborns.

For the experiment, the researchers grew samples of cytomegalovirus in their lab, purified them, then bathed them in centanamycin. Once injected into lab mice, the weakened virus infects cells but didn’t spread. Over time, the mouse immune system produced sufficient antibodies to shut down the virus and eliminate the infection.

Further analysis confirmed that the treated viral cells were not toxic to other cells in the mouse body.

The findings were published recently in Cell Reports Methods.